Newton RH, Shrestha S, Sullivan JM, et al. Maintenance of CD4 T cell fitness through regulation of Foxo1. Nat Immunol. 2018;19(8):838-848. doi:10.1038/s41590-018-0157-4.

Onder TT, Kara N, Cherry A, et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012;483(7391):598-602. doi:10.1038/nature10953.

Benassi B, Flavin R, Marchionni L, et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. 2012;2(3):236-47. doi:10.1158/2159-8290.CD-11-0219.

Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308-23. doi:10.1158/2159-8290.CD-12-0418.

Younger ST, Rinn JL. ’Lnc’-ing enhancers to MYC regulation. Cell Res. 2014;24(6):643-4. doi:10.1038/cr.2014.54.

Bar-Nur O, Brumbaugh J, Verheul C, et al. Small molecules facilitate rapid and synchronous iPSC generation. Nat Methods. 2014;11(11):1170-6. doi:10.1038/nmeth.3142.

McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med. 2014;4(10). doi:10.1101/cshperspect.a014266.

Baratta MG, Schinzel AC, Zwang Y, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015;112(1):232-7. doi:10.1073/pnas.1422165112.

Anchan R, Gerami-Naini B, Lindsey JS, et al. Efficient differentiation of steroidogenic and germ-like cells from epigenetically-related iPSCs derived from ovarian granulosa cells. PLoS One. 2015;10(3):e0119275. doi:10.1371/journal.pone.0119275.